Walleye Capital LLC Acquires Shares of 298,568 Heartflow, Inc. $HTFL

Walleye Capital LLC bought a new position in shares of Heartflow, Inc. (NASDAQ:HTFL) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 298,568 shares of the company’s stock, valued at approximately $8,760,000.

Several other hedge funds have also modified their holdings of the business. Wellington Management Group LLP purchased a new stake in shares of Heartflow in the third quarter valued at approximately $164,263,000. Schusterman Interests LLC purchased a new position in Heartflow in the third quarter worth $65,274,000. Capricorn Investment Group LLC purchased a new position in Heartflow in the fourth quarter worth $48,178,000. Vanguard Group Inc. acquired a new stake in Heartflow in the third quarter valued at $48,871,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Heartflow during the 4th quarter worth $41,714,000.

Insider Activity

In other news, insider Campbell Rogers sold 9,219 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $28.34, for a total transaction of $261,266.46. Following the completion of the transaction, the insider directly owned 78,731 shares of the company’s stock, valued at $2,231,236.54. This trade represents a 10.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 22,562 shares of Heartflow stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $28.31, for a total value of $638,730.22. Following the transaction, the chief executive officer owned 436,280 shares of the company’s stock, valued at $12,351,086.80. This represents a 4.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 115,805 shares of company stock worth $3,530,609 in the last ninety days. Insiders own 7.70% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. William Blair assumed coverage on shares of Heartflow in a research note on Monday, May 4th. They set an “outperform” rating on the stock. Benchmark reiterated a “buy” rating on shares of Heartflow in a research note on Friday. Wells Fargo & Company upped their target price on shares of Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a research report on Friday. Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings upgraded shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $43.43.

Key Heartflow News

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Heartflow reported second-quarter revenue of $64.1 million, up 47.7% year over year, while its adjusted loss of $0.07 per share beat the consensus estimate of a $0.22 loss. The results also showed improving profitability, with adjusted EBITDA losses narrowing to $6.7 million from $10.1 million a year earlier. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $246 million-$250 million from $228 million-$232 million, above the roughly $230 million analyst consensus, and projected non-GAAP gross margin of about 82%. HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
• Positive Sentiment: Growth was supported by stronger U.S. FFRCT volume and increasing adoption of the Plaque product, suggesting Heartflow’s AI-based coronary disease platform is broadening beyond its core business.
• Positive Sentiment: Analysts raised their targets following the report: JPMorgan increased its target to $45 and Stifel raised its target to $45, with both firms maintaining bullish ratings. Wells Fargo also raised its target to $39 and retained an “overweight” rating. Analyst Price Target Updates
• Neutral Sentiment: The strong move pushed the stock near its 52-week high, potentially increasing volatility and making valuation a greater consideration for investors despite improving operating trends.
• Negative Sentiment: Insiders have reported repeated open-market sales, including a 22,562-share sale by CEO John C.M. Farquhar. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but continued insider selling may still weigh on sentiment. Heartflow CEO Sells Shares

Heartflow Stock Up 35.7%

Shares of HTFL stock opened at $42.08 on Friday. The stock has a market cap of $3.63 billion and a P/E ratio of -22.99. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $43.00. The business has a fifty day simple moving average of $29.08 and a 200-day simple moving average of $27.80.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.50%. The business had revenue of $64.08 million for the quarter. The company’s revenue was up 47.7% on a year-over-year basis. On average, sell-side analysts anticipate that Heartflow, Inc. will post -0.82 earnings per share for the current year.

Heartflow Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.